Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Metastasis | Research

The risk and prognostic factors for brain metastases in esophageal cancer patients: an analysis of the SEER database

Authors: Shizhao Cheng, Lei Yang, Xin Dai, Jing Wang, Xingpeng Han

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Brain metastases were rare in esophageal cancer patients. Using the Surveillance, Epidemiology, and End Results (SEER) database, the present study investigated the incidence, risk and prognostic factors of brain metastases in esophageal cancer patients.

Methods

Retrieving esophageal cancer patients diagnosed between 2010 and 2018 from the SEER database, univariable and multivariable logistic and cox regression models were used to investigate the risk factors for brain metastases development and prognosis, respectively. The brain metastases predicting nomogram was constructed, evaluated and validated. The overall survival (OS) of patients with brain metastases was analyzed by Kaplan–Meier method.

Results

A total of 34,107 eligible esophageal cancer patients were included and 618 of them were diagnosed with brain metastases (1.8%). The median survival of the brain metastatic esophageal cancer patients was 5 (95% CI: 5–7) months. The presence of bone metastases and lung metastases were the homogeneously associated factors for the development and prognosis of brain metastases in esophageal cancer patients. Patients younger than 65 years, American Indian/Alaska Native race (vs. White), overlapping lesion (vs. Upper third), esophageal adenocarcinoma histology subtype, higher N stage, and liver metastases were positively associated with brain metastases occurrence. The calibration curve, ROC curve, and C-index exhibited good performance of the nomogram for predicting brain metastases.

Conclusions

Homogeneous and heterogeneous factors were found for the development and prognosis of brain metastases in esophageal cancer patients. The nomogram had good calibration and discrimination for predicting brain metastases.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.CrossRef

Wu S-G, Zhang W-W, Sun J-Y, Li F-Y, Lin Q, He Z-Y. Patterns of distant metastasis between histological types in esophageal cancer. Front Oncol. 2018;8:302. https://doi.org/10.3389/fonc.2018.00302.CrossRefPubMedPubMedCentral

Xiao L, Mowery YM, Czito BG, Wu Y, Gao G, Zhai C, et al. Brain metastases from esophageal squamous cell carcinoma: clinical characteristics and prognosis. Front Oncol. 2021;11:1499.

Smith RS, Miller RC. Incidence of brain metastasis in patients with esophageal carcinoma. World J Gastroenterol: WJG. 2011;17(19):2407–10. https://doi.org/10.3748/wjg.v17.i19.2407.CrossRefPubMedPubMedCentral

Zhang P, Yao L, Chen M, Feng W. Prognostic factors affecting long-term outcomes in patients with brain metastasis from esophageal carcinoma. Chin J Cancer Res. 2020;32(6):768–77. https://doi.org/10.21147/j.issn.1000-9604.2020.06.10.CrossRefPubMedPubMedCentral

Nobel TB, Dave N, Eljalby M, Xing X, Barbetta A, Hsu M, et al. Incidence and risk factors for isolated esophageal cancer recurrence to the brain. Ann Thorac Surg. 2020;109(2):329–36. https://doi.org/10.1016/j.athoracsur.2019.09.028.CrossRefPubMed

Lordick F, Mariette C, Haustermans K, Obermannová R, Arnold D. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v50–7. https://doi.org/10.1093/annonc/mdw329.CrossRefPubMed

Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004;23(13):2109–23. https://doi.org/10.1002/sim.1802.CrossRefPubMed

Ai D, Zhu H, Ren W, Chen Y, Liu Q, Deng J, et al. Patterns of distant organ metastases in esophageal cancer: a population-based study. J Thorac Dis. 2017;9(9):3023–30. https://doi.org/10.21037/jtd.2017.08.72.CrossRefPubMedPubMedCentral

10.

Wei CQ, Yuan S, Hou WH, Yuan SH. Factor analysis of brain metastasis in esophageal cancer based on SEER database. [Chinese]. Chinese J Can Prev Treat. 2020;27(10):798–802.

11.

Barz H, Barz D. Age dependence of metastases. A study of more than 5000 cases of death from cancer. Archiv fur Geschwulstforschung. 1984;54(1):77–83.PubMed

12.

McCann B, Bhatti K, MacLaren V. Incidence of brain metastasis in esophageal cancer. J Clin Oncol. 2015;33(3_suppl):46–46.CrossRef

13.

Mitra D, Clark JW, Shih HA, Oh KS, Brastianos PK, Wo JY, et al. Enrichment of HER2 amplification in brain metastases from primary gastrointestinal malignancies. Oncologist. 2019;24(2):193–201. https://doi.org/10.1634/theoncologist.2018-0152.CrossRefPubMed

14.

Feilchenfeldt J, Varga Z, Siano M, Grabsch H, Held U, Schuknecht B, et al. Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2). Br J Cancer. 2015;113(5):716–21. https://doi.org/10.1038/bjc.2015.279.CrossRefPubMedPubMedCentral

15.

Welch G, Ross HJ, Patel N, Jaroszewski D, Fleischer D, Rule W, et al. Incidence of brain metastasis from esophageal cancer. Dis Esophagus. 2017;30(9):1–6. https://doi.org/10.1093/dote/dox071.CrossRefPubMed

16.

Domeki Y, Nakajima M, Takahashi M, Kikuchi M, Yokoyama H, Ogata H, et al. Treatment strategy for brain metastases from esophageal cancer. Tumori. 2020;106(2):109–14. https://doi.org/10.1177/0300891619869518.CrossRefPubMed

17.

Lin G-S, Luo H-C, Fu Z-C, Liao S-G, Cai L-J, Zhu J-F. Does brain radiotherapy improve survival in patients with esophageal squamous cell carcinoma with brain metastasis? Ann Palliat Med. 2020;9(3):637–43. https://doi.org/10.21037/apm.2020.04.23.CrossRefPubMed

18.

Matsutani T, Hagiwara N, Nomura T, Fujita I, Kanazawa Y, Kakinuma D, et al. Long-term survival after multidisciplinary therapy for brain metastases from asymptomatic esophageal adenocarcinoma. Clin J Gastroenterol. 2018;11(2):113–7. https://doi.org/10.1007/s12328-017-0803-7.CrossRefPubMed

19.

Batson OV. The function of the vertebral veins and their role in the spread of metastases. Ann Surg. 1940;112(1):138–49. https://doi.org/10.1097/00000658-194007000-00016.CrossRefPubMedPubMedCentral

20.

Ghidini M, Petrelli F, Hahne JC, De Giorgi A, Toppo L, Pizzo C, et al. Clinical outcome and molecular characterization of brain metastases from esophageal and gastric cancer: a systematic review. Med Oncol. 2017;34(4):62. https://doi.org/10.1007/s12032-017-0919-0.CrossRefPubMed

Title: The risk and prognostic factors for brain metastases in esophageal cancer patients: an analysis of the SEER database
Authors: Shizhao Cheng
Lei Yang
Xin Dai
Jing Wang
Xingpeng Han
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Metastasis
Esophageal Cancer
Esophageal Cancer
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08802-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

LncRNA SNHG16 contributes to osteosarcoma progression by acting as a ceRNA of miR-1285-3p

Correction to: RGD4C peptide mediates anti-p21Ras scFv entry into tumor cells and produces an inhibitory effect on the human colon cancer cell line SW480

The construction and analysis of ceRNA network and patterns of immune infiltration in lung adenocarcinoma

Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma

EMMPRIN expression is associated with metastatic progression in osteosarcoma

ALDH2 polymorphism rs671 is a predictor of PD-1/PD-L1 inhibitor efficacy against thoracic malignancies

Keynote webinar | Spotlight on antibody–drug conjugates in cancer